Patrik Jeanmonod - Sep 8, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: Chief Financial Officer
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Stock symbol: CTKB
Transactions as of: Sep 8, 2022
Transactions value $: $16,000
Form type: 4
Date filed: 2/23/2023, 05:34 PM
Previous filing: Aug 25, 2022
Next filing: Sep 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Options Exercise	$16K	+40K	+52.54%	$0.40^*	116K	Sep 8, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTKB	Employee Stock Option (Right to Buy)	Options Exercise	$0	-40K	-16.48%	$0.00	203K	Sep 8, 2022	Common Stock	40K	$0.40	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Forms 4 filed after the date of the option exercise reported in this Form 4 incorrectly underreported total ownership by 40,000 shares. The number of securities beneficially owned following this option exercise is reflected as of February 17, 2022.
F2	The shares subject to the option vest as follows: 25% of the shares subject to the option vests on October 15, 2019; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.